When it comes to rare disease products, registrational trials are just the beginning of evidence generation. In this paper, we outline the key challenges and considerations related to continuous evidence generation in rare diseases.
This article is part 3 in a series. Other installments can be accessed below:
Part 1 – Understanding the Rare Disease Ecosystem
Part 2 – Optimizing Clinical Trial Design
